嵌合抗原受体（CAR）T细胞疗法有效补充了晚期复发和难治性血液癌的治疗。 CD19-和BCMA-CAR T疗法的卓越成就在血液学和肿瘤学领域引起了很高的期望。这些突破性的成功正在推动人们共同渴望将 CAR 疗法的应用范围扩展到 B 系恶性肿瘤之外。先进的 CAR 技术创造了克服传统 CAR 概念局限性的动力。最重要的是，通过组合靶向来解决靶抗原异质性的创新，使用多功能适配器 CAR 概念与最近变革性的下一代 CAR 设计相结合，有望克服与 CAR 制造和患者个性化治疗方案相关的瓶颈。在这篇全面的综述中，我们描述了基本先决条件，应对关键挑战，并阐明了战略方法，所有这些都旨在为未来使用通用 CAR 技术建立多靶点免疫疗法铺平道路。版权所有 © 2024 Schlegel、Werbrouck、Boettcher 和 Schlegel。

Chimeric antigen receptor (CAR) T cell therapy has effectively complemented the treatment of advanced relapsed and refractory hematological cancers. The remarkable achievements of CD19- and BCMA-CAR T therapies have raised high expectations within the fields of hematology and oncology. These groundbreaking successes are propelling a collective aspiration to extend the reach of CAR therapies beyond B-lineage malignancies. Advanced CAR technologies have created a momentum to surmount the limitations of conventional CAR concepts. Most importantly, innovations that enable combinatorial targeting to address target antigen heterogeneity, using versatile adapter CAR concepts in conjunction with recent transformative next-generation CAR design, offer the promise to overcome both the bottleneck associated with CAR manufacturing and patient-individualized treatment regimens. In this comprehensive review, we delineate the fundamental prerequisites, navigate through pivotal challenges, and elucidate strategic approaches, all aimed at paving the way for the future establishment of multitargeted immunotherapies using universal CAR technologies.Copyright © 2024 Schlegel, Werbrouck, Boettcher and Schlegel.